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Abstract
Introduction: The largest genetic risk to develop rheumatoid arthritis (RA) arises from a group of alleles of the HLA
DRB1 locus (’shared epitope’, SE). Over 30 non-HLA single nucleotide polymorphisms (SNPs) predisposing to disease
have been identified in Caucasians, but they have never been investigated in West/Central Africa. We previously
reported a lower prevalence of the SE in RA patients in Cameroon compared to European patients and aimed in the
present study to investigate the contribution of Caucasian non-HLA RA SNPs to disease susceptibility in Black Africans.
Methods: RA cases and controls from Cameroon were genotyped for Caucasian RA susceptibility SNPs using
Sequenom MassArray technology. Genotype data were also available for 5024 UK cases and 4281 UK controls and for
119 Yoruba individuals in Ibadan, Nigeria (YRI, HapMap). A Caucasian aggregate genetic-risk score (GRS) was calculated
as the sum of the weighted risk-allele counts.
Results: After genotyping quality control procedures were performed, data on 28 Caucasian non-HLA susceptibility
SNPs were available in 43 Cameroonian RA cases and 44 controls. The minor allele frequencies (MAF) were tightly
correlated between Cameroonian controls and YRI individuals (correlation coefficient 93.8%, p = 1.7E-13), and they
were pooled together. There was no correlation between MAF of UK and African controls; 13 markers differed by
more than 20%. The MAF for markers at PTPN22, IL2RA, FCGR2A and IL2/IL21 was below 2% in Africans. The GRS
showed a strong association with RA in the UK. However, the GRS did not predict RA in Africans (OR = 0.71, 95%
CI 0.29 - 1.74, p = 0.456). Random sampling from the UK cohort showed that this difference in association is
unlikely to be explained by small sample size or chance, but is statistically significant with p<0.001.
Conclusions: The MAFs of non-HLA Caucasian RA susceptibility SNPs are different between Caucasians and
Africans, and several polymorphisms are barely detectable in West/Central Africa. The genetic risk of developing RA
conferred by a set of 28 Caucasian susceptibility SNPs is significantly different between the UK and Africa with
p<0.001. Taken together, these observations strengthen the hypothesis that the genetic architecture of RA
susceptibility is different in different ethnic backgrounds.
Introduction
Rheumatoid arthritis (RA) is a systemic and chronic
inflammatory disease involving mainly the peripheral
joints of hands and feet initially. RA is thought to arise
from the combination of both genetic and environmental
factors. The largest genetic risk arises from a group of
alleles of the HLA-DRB1 gene, collectively referred to as
the shared epitope (SE). Candidate-gene studies and gen-
ome-wide association studies (GWASs) have identified
more than 30 non-HLA genetic loci to date [1]. The
majority of single-nucleotide polymorphisms (SNPs)
associated with RA susceptibility have been identified
and validated in patients of European ancestry who were
seropositive for either anti-citrullinated protein antibo-
dies (ACPAs) or rheumatoid factor.* Correspondence: Cem.Gabay@hcuge.ch3Division of Rheumatology, University Hospitals of Geneva, Avenue Beau-
Séjour 26, 1211 Geneva 14, Switzerland
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Several studies have shown that some validated RA
risk alleles contribute to risk in other ethnic groups, in
particular of Asian ancestry [2-4], and concluded that
some RA susceptibility loci show population-specific
associations but that others overlap between Asian and
European populations.
Ethnic differences in allele frequencies of autoimmune
disease-associated SNPs have been clearly shown [5], and
a lack of association of a particular SNP in a population
may be more likely to represent a lack of power due to
low allele frequency than to represent a true negative
effect at the individual level. The PTPN22 polymorphism
rs2476601, a cardinal example, has an allele frequency
of above 10% in healthy individuals of Northern Europe,
3% in Southern European countries, and 2% in Northern
African and African-American populations but is absent
in Asian populations [6]. However, most common SNPs
associated with RA in persons of European ancestry con-
fer risk of RA in African-Americans, whereas discordant
genetic loci appear to be the minority [7,8]. Interestingly,
the SE is associated with susceptibility to RA in African-
Americans through European genetic admixture [9], and
this is likely to be the case for several SNPs outside the
HLA-region. African-Americans and Africans, therefore,
have to be considered separately for epidemiologic and
genetic studies.
Epidemiologic and genetic data on RA in African popu-
lations are scarce. RA genetics has been studied mainly in
underpowered candidate gene association studies in
Northern and Southern Africa, and there have been few
reports in Tunisia (PTPN22 [10,11], TNFAIP3 [12],
STAT4 [13], IRF5 [14], DNASE1 [15], SUMO4 [16], and
SLAMF1 [17]), Morocco (HLA [18]), Egypt (PADI4 [19],
TRAF1/C5, and STAT4 [20]), and South Africa (HLA
[21], IL-10 [22], and p53 [23]). RA has uncommonly been
reported in Black Africans in West and Middle Africa
and its prevalence there is still unknown [24,25]. A few
studies performed from the 1960s to the 1990s on the
frequency of the disease suggested the rarity of RA in
rural West Africa [26,27]. Recent reports from West and
Middle Africa studied epidemiological, clinical, and sero-
logical profiles of RA patients in small series [25,28-31].
To the best of our knowledge, only two small genetic stu-
dies [29,32] have been performed so far in West/Middle
Africa. A study performed in Senegal showed that the
risk of developing RA was associated with HLA-DR10
but not HLA-DR4 [32]. We recently reported an impor-
tant difference in the proportion of SE-positive patients
in Cameroon compared with European patients, despite a
similar proportion of anti-cyclic citrullinated peptide
antibody (anti-CCP) positivity, suggesting that the contri-
bution of other non-HLA genetic factors to disease
susceptibility could also differ between Caucasians
and Black Africans [29]. However, no genetic study of
non-HLA markers of RA susceptibility has ever been
performed in patients originating from ethnic groups of
West or Middle Africa, although this region of Black
Africa comprises over 350 million inhabitants.
Using a previously characterized cohort of Cameroonian
patients with RA [29], we aimed to determine whether
Caucasian non-HLA RA susceptibility loci are shared with
Black African patients with RA, as has been shown for
Black Americans [7]. Because the small size of the cohort
prevented us from drawing any conclusions at the indivi-
dual SNP level, we computed an aggregated genetic risk
score (GRS) [33] to cumulatively test the association of
Caucasian RA susceptibility SNPs as a whole with disease
susceptibility in Cameroon.
Materials and methods
Patients and data collection
This study was carried out on 56 RA patients recruited
from the outpatient Rheumatology Clinic of Yaoundé
Central Hospital in Cameroon and on 50 healthy controls
recruited among medical students and hospital workers
in Yaoundé. Approval of the Cameroon National Ethical
Committee was obtained prior to the study, and
informed consent was obtained from all patients and
controls included in this study. Detailed patient and con-
trol characteristics have been reported previously [29].
Publicly available genotypes from 119 unrelated Yoruba
individuals in Ibadan, Nigeria (YRI) from the Interna-
tional HapMap Project, phases I+II+III, release #28 of
August 2010 [34,35], were incorporated in the analysis.
No phenotypic information (apart from gender) was col-
lected with the YRI samples, and medical conditions of
the donors are unknown. However, owing to the low pre-
valence of RA and other autoimmune conditions in
Nigeria, the YRI samples have been considered to be
non-RA samples and used as ‘controls’. Publicly available
allele frequencies calculated from 110 unrelated Luhya
individuals in Webuye, Kenya (LWK) from the Interna-
tional HapMap Project (release #28) were retrieved by
using SPSmart [36,37]. Nine thousand three hundred five
individuals from the UK RA Genetics Consortium
(UKRAG), comprising 5,024 RA cases and 4,281 controls,
were available for analysis. Patients’ and controls’ charac-
teristics and genotyping have been reported previously
[38]. Anti-CCP status for Cameroonian and UK samples
has been determined with the second-generation CCP
(CCP2) assay.
Single-nucleotide polymorphism selection
Caucasian confirmed RA susceptibility SNPs were selected
from the large meta-analysis by Stahl and colleagues [1].
Apart from the HLA-DRB1*0401 tag (rs6910071), all
SNPs, or good proxies (r2 >0.9 using the 1,000 Genome
reference panel for Caucasians - CEU), were available as
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part of a 67-SNP set used for high-throughput genotyping
at our laboratory. This set of SNPs has been described in
detail [39].
Genotyping
Sixty-seven SNP markers were genotyped in Cameroonian
samples by using Sequenom MassArray technology in
accordance with the instructions of the manufacturer
(Sequenom, San Diego, CA, USA). Patients with greater
than 10% missing genotype data and SNPs with less than
90% genotyping success rate or in Hardy-Weinberg dise-
quilibrium (P <0.001) were excluded, prior to analysis, as
part of quality control procedures.
Genetic risk score
A Caucasian GRS was computed according to the method
of Karlson and colleagues [33]. Briefly, 28 Caucasian con-
firmed RA susceptibility SNPs with available genotype in
the Caucasian (UKRAG) and African (Cameroon and YRI)
populations were used. Genotypes were coded as 0, 1, or
2, corresponding to the number of risk alleles carried by
an individual. Missing genotypes in UKRAG cases, con-
trols, African cases, or controls were replaced by twice the
risk allele frequency of UKRAG cases, controls, African
cases, or controls with available genotypes, respectively.
The natural logarithms of the odds ratios (ORs) taken
from the meta-analysis by Stahl and colleagues (Table 2 of
[1]) were used to weight the risk allele count and compute
the GRS. For the newly identified susceptibility markers
by Stahl and colleagues (Table 3 of [1]), the ORs from
the replication analysis were used in order to avoid the
‘winner’s curse’ effect.
Statistical analysis
All quality control steps were performed by using the
PLINK software package [40]. Subsequent statistical analy-
sis was performed with Stata version 10.1 (Stata Statistical
Software: Release 10; StataCorp LP, College Station, TX,
USA). Correlation calculations of minor allele frequencies
(MAFs) between different cohorts/populations were per-
formed by using linear regression. Association analyses
between disease susceptibility and GRS were performed
with logistic regression.
Results
Cohort characteristics and genotyping results
Cameroonian RA cases and controls collected previously
[29] were genotyped for a set of 67 susceptibility SNPs.
Basic cohort characteristics of the 43 Cameroonian
patients and 44 controls available for analysis after geno-
typing and quality control procedures do not differ from
the characteristics of the entire cohort as presented pre-
viously [29] and are compared in Table 1 with basic char-
acteristics of UK and YRI individuals. Only independent
SNPs from the meta-analysis by Stahl and colleagues
were considered for our analysis, which consisted of a set
of 32 non-HLA susceptibility SNPs. rs934734 (SPRED2)
and rs540386 (RAG1/TRAF6) completely failed genotyp-
ing. rs6859219 (ANKRD55/IL6ST) and rs10488631 (IRF5)
genotypes or proxies were not available in UKRAG.
Therefore, 28 independent confirmed Caucasian RA
non-HLA susceptibility markers (Table 2) had available
genotypes for analysis in the three datasets (Cameroon,
UKRAG, and YRI). In addition, genotypes for rs6910071,
the HLA-DRB1*0401 tag [1], were available for YRI indi-
viduals, and four-digit HLA typing was available for the
Cameroonian cohort and UKRAG.
Minor allele frequencies of Caucasian rheumatoid arthritis
susceptibility single-nucleotide polymorphisms differ
importantly between West/Central Africans and Caucasians
Nigeria and Cameroon are neighboring countries from
Central/West Africa. Although no MAF filtering was
applied and the number of Cameroonian controls was
Table 1 Summary of cohort characteristics
Cohort
Characteristics UKRAG Cameroon YRI HapMapa
Health status 1987 ACR RAb Controls 1987 ACR RAb Controls Controlsc
Number 5,024 4,281 43 44 119
Females, percentage 72 66 95 68 50
Age (IQR), yearsd 50 (39-61) - 44 (29-57)e - -
CCP-positive, percentagef 67 - 84 - -
Erosive patients, percentage 65 - 51 - -
aUnrelated individuals from the Yoruba in Ibadan, Nigeria (YRI) population, from the International HapMap Project. bSatisfying the 1987 American College of
Rheumatology classification criteria for rheumatoid arthritis (RA). cSince no phenotypic information was collected by the HapMap Consortium, medical conditions
of the YRI individuals are unknown; based on the assumed low prevalence of RA in Nigeria, ‘controls’ means that YRI individuals are unlikely to have RA and
were considered to be controls. dMedian patient age at disease onset, with interquartile range (IQR). eThe median age (IQR) at inclusion is 52 (37-61) and
therefore does not differ from the age reported for the 56 patients in the original paper [29]. fPositive for anti-cyclic citrullinated peptide antibody (anti-CCP). For
samples tested on several occasions over time, anti-CCP status was defined as positive if at least one of the tests was positive (’ever positivity’). Disease duration
at the time of the last x-ray differs between patients and cohorts. The anti-CCP status was available for only 2,842 United Kingdom Rheumatoid Arthritis Genetics
Consortium (UKRAG) patients, the rheumatoid factor status was available for 4,709 patients, and x-ray data were available for 2,851 patients, whereas there was
almost no missing information in the Cameroonian cohort.
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very low, the MAFs of the 28 Caucasian RA susceptibility
SNPs were very tightly correlated between Cameroonian
controls and YRI individuals (correlation coefficient =
93.8%, P = 1.7 × 10-13). Therefore, YRI and Cameroonian
controls were pooled together for further analysis and
referred to as African samples, totaling 206 individuals (43
cases and 163 controls). Interestingly, the MAF of Cauca-
sian RA susceptibility SNPs showed no correlation at all
between West/Central African controls and UK controls
(correlation coefficient = 30.4%, P = 0.115) (Figure 1) and
differed importantly for most of the markers considered
here: out of 28 SNPs, only 6 differ by less than 10% and
13 differ by more than 20%. rs10760130 (TRAF1/C5)
shows the strongest difference, with an allele frequency of
44%, in the UK for the G allele (minor and risk allele),
whereas the G allele is the major allele, with a frequency
of 93%, in Africa. Although the MAF is between 10% and
27% for rs12746613 (FCGR2A), rs2476601 (PTPN22),
rs6822844 (IL2/IL21), and rs2104286 (IL2RA) in the UK
controls, the MAF for those polymorphisms is below 2%
in African controls. By contrast, rs5029937 (TNFAIP3)
and rs13315591 (DNASE1L3/PXK), which display low
MAFs in the UK (3.5% and 7.8%, respectively), show a
frequency of above 40% in Africa.
Caucasian non-HLA RA susceptibility SNPs, considered in
aggregate, do not confer disease risk in Africa
The low number of African RA cases prevented an asso-
ciation study at the individual SNP level. To test the
cumulative association of 28 Caucasian non-HLA con-
firmed RA susceptibility SNPs, we computed a weighted
Caucasian GRS, a widely used strategy in complex disease
genetics to summarize the effect of multiple markers
within a single variable [33,41-44]. The Caucasian GRS
showed a strong and highly significant association with
RA in UKRAG (OR = 2.87, 95% CI 2.60 to 3.17, P = 2.7
× 10-96) when all UKRAG cases and controls were incor-
porated in the analysis. To investigate the association of
the GRS in small samples, 1,000 random samples of 43
UKRAG cases and 163 UKRAG controls were tested and
the distribution of the ORs was plotted (Figure 2). The
1,000 ORs ranged from 0.93 to 10.00. The Caucasian
GRS was computed for the African samples but did not
predict RA in this population (OR = 0.71, 95% CI 0.29 to
Table 2 Single-nucleotide polymorphisms used to
compute the genetic risk score
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6 TNFAIP3 locus 1 rs6920220
6 TNFAIP3 locus 2 rs13192841









The 28 non-HLA independent rheumatoid arthritis confirmed susceptibility
single-nucleotide polymorphisms (SNPs) plus the HLA-DRB1*0401 tag from the
meta-analysis by Stahl and colleagues [1] or proxies (in italics in the third
colomn) used in the present study are shown here.
Figure 1 Lack of correlation between minor allele frequencies
(MAFs) of non-HLA rheumatoid arthritis susceptibility single-
nucleotide polymorphisms in Caucasians (UK) and Africans. The
MAF of each polymorphism presented in Table 2 in the UK
(MAF_UK) is compared with the frequency of the same allele in
Africa (MAF_Africa). ‘Minor’ refers to a frequency of lower than 50%
in the UK. Single-nucleotide polymorphisms with an ‘MAF_Africa’ of
greater than 50% are minor alleles in the UK but major alleles in
Africa.
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1.74, P = 0.456). By contrast, the OR was smaller than the
smallest of the 1,000 ORs obtained in UK samples of the
same size (red bar in Figure 2), a situation likely to occur
by chance in less than 1 in 1,000 cases. The cumulative
association of the 28 Caucasian non-HLA RA susceptibil-
ity SNPs is therefore significantly different between the
UK and Africa (P <0.001).
Although the effects of HLA-DRB1 SE alleles have been
previously studied in the Cameroonian cohort, we com-
puted a GRS containing one more parameter: the HLA-
DRB1*0401 (hereafter, GRS_0401). rs6910071 was used as
a surrogate marker in YRI. GRS_0401 was strongly asso-
ciated with RA in URKAG (OR = 3.43, 95% CI 3.17 to
3.71, P = 8.7 × 10-206), the ORs of 1,000 random samples
ranged from 1.29 to 10.35, and the gap with the OR in
Africans (OR = 0.51, 95% CI 0.22 to 1.16, P = 0.107) was
even larger.
Discussion
The prevalence of HLA-DRB1 SE alleles is highly variable
across populations. Across Europe, for example, the pre-
valence of HLA-DRB1*0401 has been shown to vary from
4.3% in Spain to 24% in Sweden [45]. A higher prevalence
of SE alleles in a population seems to correlate with a
higher prevalence of RA [46]: the frequency of the SE is
59% in the Cree and Ojibway, a North American Native
people in central Canada who have a higher prevalence
of RA than Caucasians living in the same area. Ethnic
variations in both the frequency and types of SE-carrying
HLA-DRB1 alleles have been reported across different
populations [47], but very few studies have been per-
formed in Africa. Previously, we reported a lower preva-
lence of SE alleles in Cameroon and reviewed the scarce
literature on studies performed in Black Africans [29]. In
the present study, we investigated the contribution of
non-HLA genetic markers to RA susceptibility in Camer-
oon. In a first step, we compared the MAFs of those poly-
morphisms between different populations. In a second
step, we tested the association of confirmed Caucasian
non-HLA RA susceptibility loci ‘in aggregate’ with
disease susceptibility since the number of Cameroonian
patients with RA was very low. No study of non-HLA
genetic markers of RA susceptibility has ever been con-
ducted before in Black Africans from Central/West
Africa.
We pooled YRI individuals and Cameroonian controls
on the basis of the observation that MAFs are very similar
between those two datasets. Although samples have been
collected from two neighboring countries, population stra-
tification issues are possible. The low number of SNPs and
samples tested here prevented us from addressing this
possibility directly. There are more than 2,000 distinct lan-
guage groups in Africa; ethnic origin, language, geographi-
cal location, and genetic differences correlate, so that
population structure and genetic diversity are much larger
on the African continent than anywhere else in the world
[48,49]. Tishkoff and colleagues [49] studied 113 geogra-
phically diverse African populations, including 37 Camer-
oonian (including Bamoun, Lemande, and Bulu) and
9 Nigerian (including Yoruba) populations. Phylogenetic
and population structure analyses showed that most of the
Cameroonian populations are closely related genetically
and that the genetic distance between them and Yoruba is
small. Most Nigerian and Cameroonian populations
belong to the West/Central Africa population cluster.
However, the East Africa cluster - containing, for example,
the Luhya population in Webuye, Kenya (LWK) - is
genetically more distant. As an indirect way to estimate
the putative impact of within-population structure on our
results, we compared the MAFs of non-HLA RA suscept-
ibility loci between Cameroonian controls and LWK indi-
viduals (MAFs of 24 SNPs out of 28 studied here were
publically available for LWK; see Materials and methods).
MAFs of Cameroonian controls and LWK individuals
were as tightly correlated (correlation coefficient = 95.1%,
P = 1.2 × 10-12) as were MAFs between Cameroonian con-
trols and YRI individuals (correlation coefficient = 93.8%,
P = 1.7 × 10-13). However, there was no correlation
between MAFs of LWK and UK controls (correlation
coefficient = 22.6%, P = 0.29). These findings are compati-
ble with the out-of-Africa hypothesis of human origins
and the associated population bottlenecks, which appar-
ently resulted in the alteration of the MAFs studied here.
Figure 2 The genetic risk of developing rheumatoid arthritis
(RA) conferred by a set of 28 Caucasian non-HLA susceptibility
single-nucleotide polymorphisms is significantly different in
the UK and in Africa. One thousand random samples of 43 RA
cases and 163 controls (corresponding to the sample size of the
African dataset) were generated out of a UK dataset comprising
5,024 RA cases and 4,281 controls. The distribution of odds ratios for
association between the Caucasian genetic risk score (GRS) and
disease susceptibility is shown in yellow for Caucasian random
samples and in red for Africans.
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Given the similarity in MAFs across African populations
that are more distantly related (West and East Africa),
within-population admixture in our case control study of
Yoruba/Cameroonian individuals is unlikely to confound
the findings. Moreover, population stratification issues are
less likely to affect conclusions based on an aggregate GRS
than conclusions at the individual SNP level.
Although the sample size is small, there is no doubt that
the risk allele frequency of Caucasian RA susceptibility
loci is very different in the African samples available. The
vast majority of Caucasian susceptibility loci are common
genetic variants for reasons related to study design and
power issues. Polymorphisms with an allele frequency
close to 50% should be detected even in small samples;
however, several were barely detectable in the African con-
trol samples.
As expected, the Caucasian GRS showed a strong and
significant association in the large UK cohort studied here.
Even when 1,000 random samples of as few as 43 UK RA
cases and 163 UK controls (size of the African sample)
were tested for the association of the GRS with RA, the
vast majority of them showed an OR of larger than one
(997 of 1,000) or a P value of smaller than 0.05 (763 of
1,000). The OR in the African sample was much smaller
than the smallest OR in the UK, a situation that is extre-
mely unlikely to be explained by small sample size (P <
0.001). The effect size ratio - that is, ORUK/ORAfrica - is
4.04 (95% CI 1.6 to 10.0). Such a striking difference using
a small number of Cameroonian RA samples highlights an
important difference in the genetic architecture of RA sus-
ceptibility between the UK (or Caucasians) and Cameroon
(West/Central Africa).
Several hypotheses can be postulated to explain the
effect size ratio. First of all, the currently known Caucasian
RA susceptibility loci might constitute a minority of the
total RA susceptibility loci and might not be shared with
African patients. Indeed, many more susceptibility var-
iants, possibly thousands of SNPs, could contribute to the
susceptibility to RA [50]. Secondly, even if those markers
are shared, their effect size might be different between
Caucasians and Africans. This would explain on its own
the difference observed since the Caucasian GRS has been
computed by using the Caucasian effect sizes. Thirdly, the
confirmed RA susceptibility loci from the meta-analysis by
Stahl and colleagues [1] might not be the causal SNPs in
Caucasians but SNPs in linkage disequilibrium (LD) with
the causal SNP. Fine-mapping experiments for most of
those loci have not been performed yet. Therefore, the
causal SNP, even if shared between the two populations,
might be in tight LD with the Stahl SNPs in Caucasians
but not in Africans. Under this hypothesis, an effect size
ratio of 4.04 indicates that many of the Stahl SNPs might
not be causal. This difference in the genetic architecture of
the human genome between Africans and Caucasians can
be further illustrated at the MMEL1/TNFRSF14 locus;
rs10910099 was used as a proxy for the Stahl SNP
rs3890745. The LD (r2) between these two markers is
0.926 when the 1,000 Genome CEU (Caucasian) is used as
a reference panel but is 0.662 when the 1,000 Genome
YRI panel is used. It is not known which one of the two
SNPs, if either, is the causal.
Including the HLA-DRB1*0401 allele in the computa-
tion of the GRS further increased the gap between the
association pattern in the UK versus Africa, consistent
with previously published observations on the low allele
frequency of the HLA-DRB1*0401 allele in African
patients with RA [29,32]. Therefore, the genetics of RA
differs significantly between the UK and Cameroon in
terms of allele frequencies of currently known HLA and
non-HLA markers and their aggregate effect on disease
susceptibility. Further studies are required in larger sam-
ples of African RA patients of different origins to investi-
gate whether this statement can be generalized for
Caucasians and Black Africans. Owing to the difference in
the LD structure between Caucasians and African popula-
tions, well-powered GWASs of patients with RA will
greatly increase our understanding of the contribution of
genetic factors to disease susceptibility and allow deeper
fine-mapping experiments.
Conclusions
An aggregate GRS based on the independent and con-
firmed non-HLA Caucasian RA susceptibility SNPs pre-
dicts RA in the UK but not in West/Central Africa. The
difference in association between the GRS and disease
susceptibility is so large that it can be significantly
detected even when only 43 Cameroonian RA samples
are included in the analysis. This observation strengthens
the hypothesis that the genetic architecture of RA sus-
ceptibility is different in different ethnic backgrounds and
suggests that currently known RA susceptibility SNPs are
different or have different effect sizes between Caucasians
and Africans. Well-powered GWASs of African patients
with RA are required to identify susceptibility loci speci-
fic to ethnic groups and to contribute to the fine map-
ping of currently known loci.
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